Login
$EOCN
$3.20 +$0.12 (3.9%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q4 FY2025
As of Dec 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q4 FY2020
As of Dec 31, 2020
Q4 FY2019
As of Dec 31, 2019
Q4 FY2018
As of Dec 31, 2018
Q4 FY2017
As of Dec 31, 2017
Q4 FY2016
As of Dec 31, 2016
Q4 FY2015
As of Dec 31, 2015
Q4 FY2014
As of Dec 31, 2014
Assets
Current assets
Cash and cash equivalents
Restricted cash
Short-term deposits
Marketable debt securities
Other receivables
Total current assets
Operating lease right-of-use assets
Property and equipment, net
Investment in associate at fair value
Loan to associate
Total non-current assets
Total assets
Liabilities and stockholders’ equity
Current liabilities
Trade payables
Other payables
Total current liabilities
Stockholders’ equity
Ordinary shares, par value NIS 1.80 per share; Authorized 900,000,000 shares; Issued and outstanding: 6,581,390 and 1,664,884 shares as of December 31, 2025 and December 31, 2024, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support